ANKRD30B

Across TCGA pan-cancer cohorts, ANKRD30B RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of ANKRD30B’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where ANKRD30B RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ANKRD30B is over-expressed in tumor, although a few such as KIRC and PAAD show the opposite, repressed pattern.

BRCA, THCA, and KIRC are the cancer types where ANKRD30B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ANKRD30B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	II,III,IV	+0.794	<.001	6	view →
THCA	All	All	+0.241	<.001	6	view →
KIRC	Male	III,IV	−0.046	<.001	4	view →
PAAD	All	All	−0.057	.043	2	view →
HNSC	All	All	+0.006	.026	2	view →
ESCA	All	All	−0.192	.014	1	view →
KIRP	All	III,IV	+0.152	.047	1	view →
COAD	Female	All	−0.043	.032	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

ANKRD30B–BRCA

Open the BRCA breakdown →